Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
BEDFORD, Mass.--(BUSINESS WIRE)--Aug. 16, 2024--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today announced that, effective on August 15, 2024, the company granted stock options to purchase an aggregate of 48,400 shares of common stock to three new employees, as a material inducement to their employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Stoke Therapeutics,Inc.(纳斯达克:STOK)是一家生物技术公司,致力于通过利用RNA药物发挥身体潜能来恢复蛋白质表达。2024年8月16日,公司根据纳斯达克规定的5635(c)(4)规则,在2024年8月15日生效,向三名新员工授予购买48,400股普通股的期权作为物质诱因。
The stock options that were granted have an exercise price of $14.25 per share, which is equal to the closing price of Stoke's common stock on August 15, 2024. Each option will vest over a 4-year period, with 1/4th of the shares underlying the employee's option vesting on the one-year anniversary of the applicable vesting commencement date and the remaining shares thereafter vesting monthly at a rate of 1/48th of the shares underlying each employee's option over the following 36 months, subject to the employee's continued employment with Stoke on such vesting dates. The options have a term of 10 years and are subject to the terms and conditions of the 2023 Inducement Plan and the stock option agreement covering the grant.
授予的期权行使价格为每股14.25美元,等于2024年8月15日Stoke普通股的收盘价。每个期权将在4年期内归属,下属员工期权的1/4在适用归属开始日期一周年纪念日时归属,其余部分将以每月1/48的速度在随后36个月内归属,前提是员工在归属日继续受雇于Stoke。该期权有效期为10年,受2023年诱因计划和涵盖该授予的股票期权协议的条款和条件的约束。
About Stoke Therapeutics
关于Stoke Therapeutics
Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Using Stoke's proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Stoke's first compound, zorevunersen (STK-001), is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. Dravet syndrome is one of many diseases caused by a haploinsufficiency, in which a loss of ~50% of normal protein levels leads to disease. Stoke is pursuing the development of STK-002 for the treatment of autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder. Stoke's initial focus is haploinsufficiencies and diseases of the central nervous system and the eye, although proof of concept has been demonstrated in other organs, tissues, and systems, supporting its belief in the broad potential for its proprietary approach. Stoke is headquartered in Bedford, Massachusetts with offices in Cambridge, Massachusetts. For more information, visit .
Stoke Therapeutics是一家生物技术公司,专注于利用RNA药物发挥身体潜能以恢复蛋白质表达。利用Stoke专有的TANGO(核基因输出的有针对性增强)方法,Stoke正在开发反义寡核苷酸(ASO)以选择性地恢复蛋白质水平。Stoke的首个复合物STk-001(zorevunersen)正在临床测试,用于治疗一种严重的、渐进性的遗传性癫痫病Dravet综合症。Dravet综合症是由半等基因缺失引起的众多疾病之一,其中正常蛋白质水平的50%丧失会导致疾病的发生。Stoke正在开发STk-002用于治疗常染色体显性视神经萎缩(ADOA),这是最常见的遗传性视神经病变。Stoke最初专注于中枢神经系统和眼部的半等基因缺失和疾病,尽管已经在其他器官、组织和系统中证明了概念的可行性,支持其对其专有方法的广泛潜力的信念。Stoke总部位于马萨诸塞州的贝德福德,并在马萨诸塞州的剑桥设有办事处。欲了解更多信息,请访问。
View source version on businesswire.com:
请查看商业线(businesswire.com)的源版本。
Stoke Media & Investor Contacts:
Dawn Kalmar
Chief Communications Officer
dkalmar@stoketherapeutics.com
781-303-8302
Doug Snow
Director, Communications & Investor Relations
IR@stoketherapeutics.com
508-642-6485
Stoke媒体与投资者联系方式:
唐.卡尔马
首席通讯官
dkalmar@stoketherapeutics.com
781-303-8302
Doug Snow
董事,通信-半导体和投资者关系
IR@stoketherapeutics.com
508-642-6485
Source: Stoke Therapeutics, Inc.
资料来源:Stoke Therapeutics,Inc。